PanGenomic Health, Inc. Class A (TSE:NARA)
:NARA
Want to see TSE:NARA full AI Analyst Report?
NARA Stock Chart & Stats
C$0.51
C$0.04(33.33%)
At close: 4:00 PM EST
C$0.51
C$0.04(33.33%)
Day’s Range― - ―
52-Week RangeC$0.29 - C$2.57
Previous CloseN/A
Volume0.00
Average Volume (3M)110.39K
Market Cap
C$4.64M
Enterprise ValueC$5.71M
Total Cash (Recent Filing)C$40.85K
Total Debt (Recent Filing)C$482.87K
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding14,046,870
10 Day Avg. Volume77,322
30 Day Avg. Volume110,395
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-3.87
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Structural Industry TailwindsOperating in medical healthcare information services places the company in a secularly growing market driven by digitalization and data needs in healthcare. This enlarges long-term TAM and supports opportunities for recurring software or data services if product-market fit is achieved.
Low Absolute Reported DebtReported debt around ~483k in TTM is modest in absolute terms, limiting current interest and principal servicing burdens. For a small operator, lower nominal leverage can reduce near-term liquidity strain and buy time for restructuring, strategic partnerships, or financing.
Lean Operating FootprintA five-person workforce indicates a very lean cost base and operational agility. That structure can enable faster pivots, lower fixed overhead, and tighter control of discretionary spending, supporting runway extension and rapid execution on strategic initiatives if management prioritizes cash discipline.
Bears Say
No Revenue, Persistent LossesZero reported revenue across periods means the firm lacks a demonstrated commercialized offering and cannot show scalable unit economics. Persistent, large net losses erode investor equity and make long-term sustainability contingent on successful commercialization or continuous external funding.
Consistent Negative Cash Flow And Accelerating BurnOngoing negative operating and free cash flow with TTM operating cash flow around -2.1M indicates structural cash burn. This pattern necessitates repeated financing, increases dilution risk, and constrains the ability to invest in growth or weather downturns without clear moves to reduce burn or secure committed capital.
Negative Shareholders' Equity And Fragile Balance SheetConsistently negative shareholders' equity reflects accumulated losses and weakens solvency. Negative equity limits access to traditional debt markets, raises creditor scrutiny, and reduces financial flexibility to fund operations or pursue opportunities without equity raises that can significantly dilute existing holders.
PanGenomic Health, Inc. Class A News
NARA FAQ
What was PanGenomic Health, Inc. Class A’s price range in the past 12 months?
PanGenomic Health, Inc. Class A lowest stock price was C$0.29 and its highest was C$2.57 in the past 12 months.
What is PanGenomic Health, Inc. Class A’s market cap?
PanGenomic Health, Inc. Class A’s market cap is C$4.64M.
When is PanGenomic Health, Inc. Class A’s upcoming earnings report date?
PanGenomic Health, Inc. Class A’s upcoming earnings report date is Aug 27, 2026 which is in 74 days.
How were PanGenomic Health, Inc. Class A’s earnings last quarter?
Currently, no data Available
Is PanGenomic Health, Inc. Class A overvalued?
According to Wall Street analysts PanGenomic Health, Inc. Class A’s price is currently Overvalued.
Does PanGenomic Health, Inc. Class A pay dividends?
PanGenomic Health, Inc. Class A does not currently pay dividends.
What is PanGenomic Health, Inc. Class A’s EPS estimate?
PanGenomic Health, Inc. Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PanGenomic Health, Inc. Class A have?
PanGenomic Health, Inc. Class A has 14,046,870 shares outstanding.
What happened to PanGenomic Health, Inc. Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PanGenomic Health, Inc. Class A?
Currently, no hedge funds are holding shares in TSE:NARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PanGenomic Health, Inc. Class A
Pangenomic Health Inc., a precision health enterprise, develops a digital self-care platform designed to deliver personalized, scientifically-backed information on natural treatments for mental well-being. This platform includes the Nara App, a mobile application for consumers that offers a knowledge base tailored to individual user profiles. Additionally, the company provides the PlantGx Platform, a digital therapeutics solution for clinics, enabling healthcare professionals to access patient health data (with patient authorization) originating from the Nara App and facilitating patient referrals. The firm, established in 2015, previously operated as Zetta Capital Corp. before rebranding to PanGenomic Health Inc. in December 2021. Its headquarters are located in Vancouver, Canada.
Technical Analysis
Diagnos
―
nDatalyze Corp
―
Rocket Doctor AI
―
UniDoc Health Corp
―
DiagnaMed Holdings Corp.
―
Options Prices
Currently, No data available
---